Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, Inc. ($TSHA), sold nearly $4 million worth of company shares in seven open market transactions over the last 365 days, with the most recent on January 26, 2026. These $TSHA insider sales rank 2,254th among over 11,600 individuals in our database, below the average of $8.6 million per seller and 6.4 transactions. Sukumar made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 26, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 26918 | $4.61 | 1,317,389.0000 | 353,309,524 | 2.00% | 0.01% |
| Jan. 23, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 89132 | $4.75 | 1,344,307.0000 | 353,309,524 | 6.22% | 0.03% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 88676 | $0.00 | 474,941.0000 | 353,309,524 | 15.73% | 0.03% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 111324 | $0.00 | 111,359.0000 | 353,309,524 | 49.99% | 0.03% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Common Stock | 427000 | $0.00 | 1,433,439.0000 | 353,309,524 | 42.43% | 0.12% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 200000 | $4.71 | 1,006,439.0000 | 353,309,524 | 16.58% | 0.06% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 111324 | $0.70 | 1,117,763.0000 | 353,309,524 | 11.06% | 0.03% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 88676 | $1.71 | 1,206,439.0000 | 353,309,524 | 7.93% | 0.03% |
| Jan. 12, 2026 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Employee Stock Option (right to buy) | 274000 | $0.00 | 274,000.0000 | 353,309,524 | 9999.99% | 0.08% |
| Dec. 1, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 260047 | $1.71 | 1,266,486.0000 | 353,309,524 | 25.84% | 0.07% |
| Nov. 28, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 70172 | $0.70 | 1,076,611.0000 | 353,309,524 | 6.97% | 0.02% |
| Nov. 28, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 39953 | $1.71 | 1,116,564.0000 | 353,309,524 | 3.71% | 0.01% |
| Nov. 28, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 110125 | $4.75 | 1,006,439.0000 | 353,309,524 | 9.86% | 0.03% |
| Dec. 1, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 260047 | $4.51 | 1,006,439.0000 | 353,309,524 | 20.53% | 0.07% |
| Nov. 28, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 70172 | $0.00 | 222,683.0000 | 353,309,524 | 23.96% | 0.02% |
| Nov. 28, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 39953 | $0.00 | 823,664.0000 | 353,309,524 | 4.63% | 0.01% |
| Dec. 1, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 260047 | $0.00 | 563,617.0000 | 353,309,524 | 31.57% | 0.07% |
| Sept. 10, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 200000 | $3.23 | 1,006,439.0000 | 250,134,421 | 16.58% | 0.08% |
| Sept. 10, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Employee Stock Option (right to buy) | 41150 | $0.00 | 292,855.0000 | 250,134,421 | 12.32% | 0.02% |
| Sept. 10, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | M | Common Stock | 41150 | $0.70 | 1,206,439.0000 | 250,134,421 | 3.53% | 0.02% |
| Aug. 21, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | S | Common Stock | 57054 | $2.85 | 1,165,289.0000 | 250,134,421 | 4.67% | 0.02% |
| June 12, 2025 | Solid Biosciences Inc. | $SLDB | Nagendran Sukumar | Not found | A | Director Stock Option (Right to Buy) | 77500 | $0.00 | 77,500.0000 | 40,816,694 | 9999.99% | 0.19% |
| Jan. 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Common Stock | 324500 | $0.00 | 1,222,343.0000 | 250,134,421 | 36.14% | 0.13% |
| Jan. 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Employee Stock Option (right to buy) | 324500 | $0.00 | 324,500.0000 | 250,134,421 | 9999.99% | 0.13% |
| June 11, 2024 | Solid Biosciences Inc. | $SLDB | Nagendran Sukumar | Not found | A | Director Stock Option (Right to Buy) | 34400 | $0.00 | 34,400.0000 | 19,884,007 | 9999.99% | 0.17% |
| Jan. 2, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Employee Stock Option (right to buy) | 863617 | $0.00 | 863,617.0000 | 116,121,482 | 9999.99% | 0.74% |
| Jan. 2, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Nagendran Sukumar | President and Head of R&D | A | Common Stock | 863617 | $0.00 | 897,843.0000 | 116,121,482 | 2523.28% | 0.74% |